Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Is mizoribine a new therapeutic agent for Sjögren's syndrome?

Moutsopoulos HM, Fragoulis GE.

Nat Clin Pract Rheumatol. 2008 Jul;4(7):350-1. doi: 10.1038/ncprheum0823. Epub 2008 May 27.

PMID:
18506160
2.

A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome.

Khurshudian AV.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Jan;95(1):38-44.

PMID:
12539025
3.

Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial.

Nakayamada S, Saito K, Umehara H, Ogawa N, Sumida T, Ito S, Minota S, Nara H, Kondo H, Okada J, Mimori T, Yoshifuji H, Sano H, Hashimoto N, Sugai S, Tanaka Y.

Mod Rheumatol. 2007;17(6):464-9. Epub 2007 Dec 20.

PMID:
18084697
4.

Efficacy of mizoribine treatment in patients with Sjögren's syndrome: an open pilot trial.

Nakayamada S, Saito K, Nakatsuka K, Nakano K, Tokunaga M, Sawamukai N, Tsujimura S, Nawata M, Tanaka Y.

Mod Rheumatol. 2003 Dec;13(4):339-45. doi: 10.3109/s10165-003-0247-4.

PMID:
24387256
5.

Successful Treatment of Dry Mouth and Dry Eye Symptoms in Sjögren's Syndrome Patients With Oral Pilocarpine: A Randomized, Placebo-Controlled, Dose-Adjustment Study.

Papas AS, Sherrer YS, Charney M, Golden HE, Medsger TA Jr, Walsh BT, Trivedi M, Goldlust B, Gallagher SC.

J Clin Rheumatol. 2004 Aug;10(4):169-77.

PMID:
17043506
6.

Opening the flood gates: interferon-alpha treatment for Sjögren's syndrome.

Shiozawa S, Cummins JM, Fox PC.

BioDrugs. 2000 May;13(5):305-11.

PMID:
18034537
7.

[Generic quetiapine in the treatment of acute schizophrenia and schizoaffective disorder].

György B, Robert K, László C, Andrea J; Ketilept Vizsgáló Munkacsoport.

Neuropsychopharmacol Hung. 2008 Dec;10(5):293-303. Hungarian.

8.

[Applicability of syalometry and other instruments to evaluate xerostomia and xerophtalmia in a Sjögren's Syndrome outpatient clinic].

Barcelos F, Patto JV, Parente M, Medeiros D, Sousa M, Figueiredo R, Miguel C, Teixeira A.

Acta Reumatol Port. 2009 Apr-Jun;34(2A):212-8. Portuguese.

9.

Increased prevalence of antibodies to thyroid peroxidase in dry eyes and mouth syndrome or sicca asthenia polyalgia syndrome.

Mavragani CP, Skopouli FN, Moutsopoulos HM.

J Rheumatol. 2009 Aug;36(8):1626-30. doi: 10.3899/jrheum.081326. Epub 2009 Jul 15.

PMID:
19605678
10.

The Sjögren's Syndrome Damage Index--a damage index for use in clinical trials and observational studies in primary Sjögren's syndrome.

Barry RJ, Sutcliffe N, Isenberg DA, Price E, Goldblatt F, Adler M, Canavan A, Hamburger J, Richards A, Regan M, Gadsby K, Rigby S, Jones A, Mathew R, Mulherin D, Stevenson A, Nightingale P, Rauz S, Bowman SJ.

Rheumatology (Oxford). 2008 Aug;47(8):1193-8. doi: 10.1093/rheumatology/ken164. Epub 2008 Jun 4.

PMID:
18524804
11.

Salivary resistin reflects local inflammation in Sjögren's syndrome.

Boström EA, d'Elia HF, Dahlgren U, Simark-Mattsson C, Hasséus B, Carlsten H, Tarkowski A, Bokarewa M.

J Rheumatol. 2008 Oct;35(10):2005-11. Epub 2008 Aug 15.

PMID:
18709689
12.

Primary Sjogren's syndrome with central nervous system involvement.

Alhomoud IA, Bohlega SA, Alkawi MZ, Alsemari AM, Omer SM, Alsenani FM.

Saudi Med J. 2009 Aug;30(8):1067-72.

PMID:
19668890
13.

An open-label tolerability and efficacy study of an aluminum sesquichlorohydrate topical foam in axillary and palmar primary hyperhidrosis.

Innocenzi D, Ruggero A, Francesconi L, Lacarrubba F, Nardone B, Micali G.

Dermatol Ther. 2008 Jul;21 Suppl 1:S27-30. doi: 10.1111/j.1529-8019.2008.00199.x.

PMID:
18727813
14.

Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational study.

Feuerhake C, Buchholz P, Kimmich F.

Curr Med Res Opin. 2009 Apr;25(4):1037-43. doi: 10.1185/03007990902816947 .

PMID:
19290780
15.

Tizanidine is effective in the treatment of myofascial pain syndrome.

Malanga GA, Gwynn MW, Smith R, Miller D.

Pain Physician. 2002 Oct;5(4):422-32.

16.

Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren's syndrome.

Rihl M, Ulbricht K, Schmidt RE, Witte T.

Rheumatology (Oxford). 2009 Jul;48(7):796-9. doi: 10.1093/rheumatology/kep104. Epub 2009 May 11.

PMID:
19433433
17.

Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder.

Homma Y, Yamaguchi O.

Int J Urol. 2008 Oct;15(11):986-91. doi: 10.1111/j.1442-2042.2008.02152.x. Epub 2008 Aug 28.

18.

Minor salivary gland immunohistology in the diagnosis of primary Sjögren's syndrome.

Salomonsson S, Rozell BL, Heimburger M, Wahren-Herlenius M.

J Oral Pathol Med. 2009 Mar;38(3):282-8. doi: 10.1111/j.1600-0714.2008.00697.x. Epub 2008 Sep 12.

PMID:
18793250
19.

A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial).

Altman RD, Rosen JE, Bloch DA, Hatoum HT, Korner P.

Semin Arthritis Rheum. 2009 Aug;39(1):1-9. doi: 10.1016/j.semarthrit.2009.04.001. Epub 2009 Jun 17.

PMID:
19539353
20.

Are cannabinoids a new treatment option for pain in patients with fibromyalgia?

Staud R, Koo EB.

Nat Clin Pract Rheumatol. 2008 Jul;4(7):348-9. doi: 10.1038/ncprheum0826. Epub 2008 Jun 3.

PMID:
18521112

Supplemental Content

Support Center